Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
Podcasts
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
Podcasts
About
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
DMARDs, disease modifying antirheumatic drugs
Email alerts
DMARDs, disease modifying antirheumatic drugs
Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment
A S
Russell
,
G V
Wallenstein
,
T
Li
,
M C
Martin
,
R
Maclean
,
B
Blaisdell
,
K
Gajria
,
J C
Cole
,
J-C
Becker
,
P
Emery
Annals of the Rheumatic Diseases
Feb 2007,
66
(2)
189-194;
DOI:
10.1136/ard.2006.057018
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
A
Finckh
,
J F
Simard
,
C
Gabay
,
P-A
Guerne
Annals of the Rheumatic Diseases
Jun 2006,
65
(6)
746-752;
DOI:
10.1136/ard.2005.045062
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
M E
Weinblatt
,
E C
Keystone
,
D E
Furst
,
A F
Kavanaugh
,
E K
Chartash
,
O G
Segurado
Annals of the Rheumatic Diseases
Jun 2006,
65
(6)
753-759;
DOI:
10.1136/ard.2005.044404
Swedish registers to examine drug safety and clinical issues in RA
J
Askling
,
C M
Fored
,
P
Geborek
,
L T H
Jacobsson
,
R
van Vollenhoven
,
N
Feltelius
,
S
Lindblad
,
L
Klareskog
Annals of the Rheumatic Diseases
Jun 2006,
65
(6)
707-712;
DOI:
10.1136/ard.2005.045872
High dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of host autoantibodies and synovial abnormalities
M
van Oosterhout
,
R J
Verburg
,
E W N
Levarht
,
J D
Moolenburgh
,
R M
Barge
,
W E
Fibbe
,
J M
van Laar
Annals of the Rheumatic Diseases
Dec 2005,
64
(12)
1783-1785;
DOI:
10.1136/ard.2004.034793
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis
V P K
Nell
,
K P
Machold
,
T A
Stamm
,
G
Eberl
,
H
Heinzl
,
M
Uffmann
,
J S
Smolen
,
G
Steiner
Annals of the Rheumatic Diseases
Dec 2005,
64
(12)
1731-1736;
DOI:
10.1136/ard.2005.035691
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression
J
Rönnelid
,
M C
Wick
,
J
Lampa
,
S
Lindblad
,
B
Nordmark
,
L
Klareskog
,
R F
van Vollenhoven
Annals of the Rheumatic Diseases
Dec 2005,
64
(12)
1744-1749;
DOI:
10.1136/ard.2004.033571
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis
L
Gossec
,
D
van der Heijde
,
A
Melian
,
D A
Krupa
,
M K
James
,
P F
Cavanaugh
,
A S
Reicin
,
M
Dougados
Annals of the Rheumatic Diseases
Nov 2005,
64
(11)
1563-1567;
DOI:
10.1136/ard.2004.029611
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study
H
Marzo-Ortega
,
D
McGonagle
,
S
Jarrett
,
G
Haugeberg
,
E
Hensor
,
P
O’Connor
,
A L
Tan
,
P G
Conaghan
,
A
Greenstein
,
P
Emery
Annals of the Rheumatic Diseases
Nov 2005,
64
(11)
1568-1575;
DOI:
10.1136/ard.2004.022582
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
G
Kobelt
,
P
Lindgren
,
A
Singh
,
L
Klareskog
Annals of the Rheumatic Diseases
Aug 2005,
64
(8)
1174-1179;
DOI:
10.1136/ard.2004.032789
Pages
1
2
next ›
last »
CLINICAL
Diagnostics
Clinical diagnostic tests
(1563)
Radiology (diagnostics)
(921)
Surgical diagnostic tests
(505)
Drugs and medicines
Endocrinology
Calcium and bone
(938)
Evidence based practice
Guidelines
(35)
Gastroenterology
Inflammatory bowel disease
(98)
Genetics
(1272)
Immunology (including allergy)
(6648)
Infectious diseases
Bone and joint infections
(93)
Travel medicine
(42)
Neurology
Muscle disease
(198)
Pain (neurology)
(1113)
Nutrition and metabolism
Obesity (nutrition)
(142)
Obstetrics and gynaecology
Menopause (including HRT)
(60)
Ophthalmology
(155)
Orthopaedics
Pathology
Inflammation
(1572)
Pathology
(531)
Pharmacology and therapeutics
Unwanted effects / adverse reactions
(15)
Pharmacology and therapeutics
Radiology
(1357)
Rehabilitation medicine
Disability
(32)
Other rehabilitative therapies
(18)
Physiotherapy
(52)
Renal medicine
(247)
Respiratory medicine
Interstitial lung disease
(181)
Pulmonary hypertension
(39)
Rheumatology
Ankylosing spondylitis
(567)
Biological agents
(731)
Connective tissue disease
(5506)
Degenerative joint disease
(6038)
Drugs: musculoskeletal and joint diseases
(916)
Fibromyalgia
(51)
Musculoskeletal syndromes
(6412)
Osteoarthritis
(1189)
Osteoporosis
(160)
Rheumatoid arthritis
(4213)
Sjogren's syndrome
(6)
Systemic lupus erythematosus
(724)
Vascularitis
(367)
Sports and exercise medicine
Physiotherapy
(33)
NON-CLINICAL
Epidemiology
(1862)
Health economics
(51)
Medical education
Postgraduate
(5)
Occupational and environmental medicine
(32)
Statistics and research methods
Special collections
ARD Lay summaries
(83)
Editor's choice
(161)
Guidelines, Recommendations and Consensus Statements
Open access
(1199)
Press releases
(50)